SCHEMBL1734479

SCHEMBL1734479

COc1cccc(C(=O)c2ccccc2)c1S(=O)(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
LMNA P02545 4/20 0.57
KMT2A Q03164 3/20 0.57
ALDH1A1 P00352 2/20 0.57
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
STS P08842 1/20 0.51
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
RECQL P46063 1/20 0.50
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NPC1 O15118 3/20 0.48
TP53 P04637 1/20 0.47
GAA P10253 1/20 0.47
ELANE P08246 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8361898 0.88 STS (0.50) MAPTLMNAKMT2AALDH1A1HSD17B10
SCHEMBL499856 0.85 STS (0.49) MAPTLMNAKMT2AALDH1A1KDM4E
SCHEMBL18762908 0.84 SLC6A3 (0.46) MAPTLMNAKMT2AALDH1A1STS
SCHEMBL2859044 0.84 STS (0.48) MAPTLMNAKMT2AALDH1A1KDM4E
SCHEMBL9815155 0.84 HTT (0.53) MAPTKMT2AALDH1A1KDM4EHSD17B10
SCHEMBL8431039 0.82 MAPT (0.42) MAPTLMNAKMT2AALDH1A1KDM4E
SCHEMBL500619 0.82 MAPT (0.56) MAPTLMNAKMT2AALDH1A1KDM4E
SCHEMBL717833 0.82 MAPT (0.68) MAPTLMNAKMT2AALDH1A1KDM4E
SCHEMBL689017 0.82 MAPT (0.42) MAPTLMNAKMT2AALDH1A1STS
SCHEMBL11320168 0.81 MAPT (0.60) MAPTLMNAKMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172185-B1 Cosmetic material comprising octyl hydroxy stearate oligomer PARAHERMOSA CO LTD (JP) 2011-11-23 EP claimed
WO-2008083975-A1 LIGHT-STABILIZED COMPOSITION ISDIN S.A. (ES) 2008-07-17 WO claimed
US-20080131384-A1 External Preparation for Skin Whitening, Whitening Agent, Whitening Method and Method of Production of External Preparation for Skin Whitening SHISEIDO COMPANY, LTD. (JP) 2008-06-05 US disclosed
US-7176217-B2 Azabicyclo compound matrix metalloprotease inhibitor and skin preparation SHISEIDO CO., LTD. (JP) 2007-02-13 US disclosed
US-20050009808-A1 Azabicyclo compound matrix metalloprotease inibitor and skin preparation SHISEIDO CO., LTD. (JP) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009808-A1 Azabicyclo compound matrix metalloprotease inibitor and skin preparation MMP1, MMP16, MMP9 MAPT 4818/4885LMNA 2771/4885KMT2A 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.